BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 31361072)

  • 21. Genetic and epigenetic alterations during renal carcinogenesis.
    Arai E; Kanai Y
    Int J Clin Exp Pathol; 2010 Dec; 4(1):58-73. PubMed ID: 21228928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A construction and comprehensive analysis of ceRNA networks and infiltrating immune cells in papillary renal cell carcinoma.
    Fan Y; Dai F; Yuan M; Wang F; Wu N; Xu M; Bai Y; Liu Y
    Cancer Med; 2021 Nov; 10(22):8192-8209. PubMed ID: 34598322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pan-cancer perspective analysis reveals the opposite prognostic significance of CD133 in lower grade glioma and papillary renal cell carcinoma.
    Wang H; Wang X; Xu L; Zhang J; Cao H
    Sci Prog; 2021; 104(2):368504211010938. PubMed ID: 33878963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ex Vivo Drug Testing in Patient-derived Papillary Renal Cancer Cells Reveals EGFR and the BCL2 Family as Therapeutic Targets.
    Angori S; Banaei-Esfahani A; Mühlbauer K; Bolck HA; Kahraman A; Karakulak T; Poyet C; Feodoroff M; Potdar S; Kallioniemi O; Pietiäinen V; Schraml P; Moch H
    Eur Urol Focus; 2023 Sep; 9(5):751-759. PubMed ID: 36933996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioinformatics Analysis Identifies Protein Tyrosine Kinase 7 (PTK7) as a Potential Prognostic and Therapeutic Biomarker in Stages I to IV Hepatocellular Carcinoma.
    Zou RC; Liang Y; Li LL; Tang JZ; Yang YP; Geng YC; He J; Luo LY; Li WX; Sun ZW; Yuan HL
    Med Sci Monit; 2019 Nov; 25():8618-8627. PubMed ID: 31730575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-cell chromatin accessibility landscape in kidney identifies additional cell-of-origin in heterogenous papillary renal cell carcinoma.
    Wang Q; Zhang Y; Zhang B; Fu Y; Zhao X; Zhang J; Zuo K; Xing Y; Jiang S; Qin Z; Li E; Guo H; Liu Z; Yang J
    Nat Commun; 2022 Jan; 13(1):31. PubMed ID: 35013217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Warthin-like papillary renal cell carcinoma: Clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 11 cases.
    Skenderi F; Ulamec M; Vanecek T; Martinek P; Alaghehbandan R; Foix MP; Babankova I; Montiel DP; Alvarado-Cabrero I; Svajdler M; Dubinský P; Cempirkova D; Pavlovsky M; Vranic S; Daum O; Ondic O; Pivovarcikova K; Michalova K; Hora M; Rotterova P; Stehlikova A; Dusek M; Michal M; Hes O
    Ann Diagn Pathol; 2017 Apr; 27():48-56. PubMed ID: 28325361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
    Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
    BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological, genetic, ultrastructural characterizations and prognostic factors of papillary renal cell carcinoma: new diagnostic and prognostic information.
    Yu W; Zhang W; Jiang Y; Wang Y; Li Y; Wang J; Sun L; Ran W; Li H
    Acta Histochem; 2013 Jun; 115(5):452-9. PubMed ID: 23219441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic risk signature based on the expression of three m6A RNA methylation regulatory genes in kidney renal papillary cell carcinoma.
    Sun Z; Jing C; Xiao C; Li T; Wang Y
    Aging (Albany NY); 2020 Nov; 12(21):22078-22094. PubMed ID: 33177247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.
    Durinck S; Stawiski EW; Pavía-Jiménez A; Modrusan Z; Kapur P; Jaiswal BS; Zhang N; Toffessi-Tcheuyap V; Nguyen TT; Pahuja KB; Chen YJ; Saleem S; Chaudhuri S; Heldens S; Jackson M; Peña-Llopis S; Guillory J; Toy K; Ha C; Harris CJ; Holloman E; Hill HM; Stinson J; Rivers CS; Janakiraman V; Wang W; Kinch LN; Grishin NV; Haverty PM; Chow B; Gehring JS; Reeder J; Pau G; Wu TD; Margulis V; Lotan Y; Sagalowsky A; Pedrosa I; de Sauvage FJ; Brugarolas J; Seshagiri S
    Nat Genet; 2015 Jan; 47(1):13-21. PubMed ID: 25401301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fifteen hub genes associated with progression and prognosis of clear cell renal cell carcinoma identified by coexpression analysis.
    Wang Y; Chen L; Wang G; Cheng S; Qian K; Liu X; Wu CL; Xiao Y; Wang X
    J Cell Physiol; 2019 Jul; 234(7):10225-10237. PubMed ID: 30417363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High CENPA expression in papillary renal cell carcinoma tissues is associated with poor prognosis.
    Li J; Li Q; Yuan Y; Xie Y; Zhang Y; Zhang R
    BMC Urol; 2022 Sep; 22(1):157. PubMed ID: 36163007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
    Zhao H; Leppert JT; Peehl DM
    PLoS One; 2016; 11(1):e0146505. PubMed ID: 26814892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA ploidy pattern in papillary renal cell carcinoma. Correlation with clinicopathological parameters and survival.
    del Vecchio MT; Lazzi S; Bruni A; Mangiavacchi P; Cevenini G; Luzi P
    Pathol Res Pract; 1998; 194(5):325-33. PubMed ID: 9651945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The genomic and epigenomic evolutionary history of papillary renal cell carcinomas.
    Zhu B; Poeta ML; Costantini M; Zhang T; Shi J; Sentinelli S; Zhao W; Pompeo V; Cardelli M; Alexandrov BS; Otlu B; Hua X; Jones K; Brodie S; Dabrowska ME; Toro JR; Yeager M; Wang M; Hicks B; Alexandrov LB; Brown KM; Wedge DC; Chanock S; Fazio VM; Gallucci M; Landi MT
    Nat Commun; 2020 Jun; 11(1):3096. PubMed ID: 32555180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA methylation of tumor associated calcium signal transducer 2 (TACSTD2) loci shows association with clinically aggressive renal cell cancers.
    Katzendorn O; Peters I; Dubrowinskaja N; Tezval H; Tabrizi PF; von Klot CA; Hennenlotter J; Lafos M; Kuczyk MA; Serth J
    BMC Cancer; 2021 Apr; 21(1):444. PubMed ID: 33882870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The molecular characterization and therapeutic strategies of papillary renal cell carcinoma.
    Chen Q; Cheng L; Li Q
    Expert Rev Anticancer Ther; 2019 Feb; 19(2):169-175. PubMed ID: 30474436
    [No Abstract]   [Full Text] [Related]  

  • 39. Oncocytic papillary renal cell carcinoma: A clinicopathological and genetic analysis and indolent clinical course in 14 cases.
    Han G; Yu W; Chu J; Liu Y; Jiang Y; Li Y; Zhang W
    Pathol Res Pract; 2017 Jan; 213(1):1-6. PubMed ID: 27931799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-coding RNA and gene expression analyses of papillary renal neoplasm with reverse polarity (PRNRP) reveal distinct pathological mechanisms from other renal neoplasms.
    Nemours S; Armesto M; Arestín M; Manini C; Giustetto D; Sperga M; Pivovarcikova K; Pérez-Montiel D; Hes O; Michal M; López JI; Lawrie CH
    Pathology; 2024 Jun; 56(4):493-503. PubMed ID: 38413252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.